These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707 [TBL] [Abstract][Full Text] [Related]
163. Increased Incidence of Critical Illness in Psoriasis. Marrie RA; Bernstein CN; Peschken CA; Hitchon CA; Chen H; Garland A J Cutan Med Surg; 2017; 21(5):395-400. PubMed ID: 28587481 [TBL] [Abstract][Full Text] [Related]
164. Interleukin 23 inhibitors for psoriasis: not just another number. Bachelez H Lancet; 2017 Jul; 390(10091):208-210. PubMed ID: 28596042 [No Abstract] [Full Text] [Related]
165. Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis. Oka T; Sugaya M; Takahashi N; Nakajima R; Otobe S; Kabasawa M; Suga H; Miyagaki T; Asano Y; Sato S Acta Derm Venereol; 2017 Nov; 97(10):1172-1177. PubMed ID: 28597022 [TBL] [Abstract][Full Text] [Related]
166. Brief Report: Interleukin-17A-Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation. Charruyer A; Fong S; Vitcov GG; Sklar S; Tabernik L; Taneja M; Caputo M; Soeung C; Yue L; Uchida Y; Arron ST; Horton KM; Foster RD; Sano S; North JP; Ghadially R Stem Cells; 2017 Aug; 35(8):2001-2007. PubMed ID: 28600817 [TBL] [Abstract][Full Text] [Related]
167. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039 [TBL] [Abstract][Full Text] [Related]
168. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. Gladman DD; Poulin Y; Adams K; Bourcier M; Barac S; Barber K; Chandran V; Dutz J; Flanagan C; Gooderham MJ; Gulliver WP; Ho VC; Hong CH; Karsh J; Khraishi MM; Lynde CW; Papp KA; Rahman P; Rohekar S; Rosen CF; Russell AS; Vender RB; Yeung J; Ziouzina O; Zummer M J Rheumatol; 2017 Apr; 44(4):519-534. PubMed ID: 28604347 [TBL] [Abstract][Full Text] [Related]
169. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis. Lee YH; Song GG Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775 [TBL] [Abstract][Full Text] [Related]
170. Clinicians' perspectives of shared care of psoriatic arthritis and psoriasis between rheumatology and dermatology: an interview study. Sumpton D; Hannan E; Kelly A; Tunnicliffe D; Ming A; Hassett G; Craig JC; Tong A Clin Rheumatol; 2021 Apr; 40(4):1369-1380. PubMed ID: 32935247 [TBL] [Abstract][Full Text] [Related]
171. Prevalence, clinical features and treatment pattern of patients with concurrent diagnoses of rheumatoid arthritis and psoriatic disease: results of a 14-year retrospective study in a tertiary referral center. Chen KL; Chiu HY; Lin JH; Ye JD; Cho YH; Li KJ; Tsai TF Ther Adv Chronic Dis; 2019; 10():2040622319847900. PubMed ID: 31205646 [TBL] [Abstract][Full Text] [Related]
172. Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach. Visalli E; Crispino N; Foti R Adv Ther; 2019 Apr; 36(4):806-816. PubMed ID: 30805821 [TBL] [Abstract][Full Text] [Related]
173. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Lebwohl MG; Kavanaugh A; Armstrong AW; Van Voorhees AS Am J Clin Dermatol; 2016 Feb; 17(1):87-97. PubMed ID: 26718712 [TBL] [Abstract][Full Text] [Related]
174. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Gottlieb A; Gratacos J; Dikranian A; van Tubergen A; Fallon L; Emir B; Aikman L; Smith T; Chen L Rheumatol Int; 2019 Jan; 39(1):121-130. PubMed ID: 30426237 [TBL] [Abstract][Full Text] [Related]
175. The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan. Li TH; Liao HT; Huang YF; Shen YC; Chiu YC; Chen WS; Chen MH; Tsai CY; Chang DM J Formos Med Assoc; 2018 May; 117(5):404-412. PubMed ID: 28552625 [TBL] [Abstract][Full Text] [Related]
176. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420 [TBL] [Abstract][Full Text] [Related]
177. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916 [TBL] [Abstract][Full Text] [Related]